1.74 USD
↘ 0.07 (3.87%)AT CLOSE (11:59 AM EDT)
Annovis Bio, Inc.
ANVSNYSE • USD
1.79
↗ 0.05 (3.10%)
POST MARKET (AS OF 08:13 PM EDT)
Post Market
AS OF 08:13 PM EDT
1.79
↗ 0.05 (3.10%)
Market: CLOSED
Open?$1.73
High?$1.82
Low?$1.73
Prev. Close?$1.81
Volume?872.1K
Avg. Volume?1.0M
VWAP?$1.77
Rel. Volume?0.84x
Bid / Ask
Bid?$1.73 × 100
Ask?$1.80 × 500
Spread?$0.07
Midpoint?$1.77
Valuation & Ratios
Market Cap?60.1M
Shares Out?29.3M
Float?22.2M
Float %?83.9%
P/E Ratio?N/A
P/B Ratio?3.57
EPS?-$0.84
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.80Strong
Quick Ratio?5.80Strong
Cash Ratio?5.37Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score83/100
P/E?N/A▾
P/B?3.57FAIR▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.4CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-171.2%WEAK▾
ROA?-136.9%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$40.6M
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Employees
7
Market Cap
60.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2020-01-29
Address
101 LINDENWOOD DRIVE, SUITE 225
MALVERN, PA 19355
Phone: 484-875-3192
MALVERN, PA 19355
Phone: 484-875-3192